Skip to content

Gait Rehabilitation in Stroke Patients Using Functional Electrical Stimulation and Visual Feedback

A Randomized Controlled Pilot Study of Gait Rehabilitation in Stroke Patients Using Functional Electrical Stimulation and Visual Feedback

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07537530
Acronym
BrainSTEP
Enrollment
30
Registered
2026-04-17
Start date
2025-06-03
Completion date
2026-04-02
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Brain-Computer Interface, Neurofeedback, EEG feedback, Electrical Stimulation Therapy, Virtual reality

Brief summary

recoveriX PRO system is a Brain-Computer Interface (BCI) device that combines Motor Imagination (MI), with Functional Electrical Stimulation (FES) and Virtual Reality (VR) as feedback devices. The user wears an electroencephalography (EEG) cap that registers the neural activity during the mental practice. This system allows the user to control the feedback devices (FES +VR) with the MI. The goal of this clinical trial is to know the safety and clinical effectiveness of recoveriX-based treatment for improving gait functions in stroke patients. Researchers will compare the functional results obtained by recoveriX system, to the standard treatment based in FES + VR + MI without monitoring the EEG activity. The questions to answer are: 1. Will stroke patients who undergo recoveriX therapy significantly improve their gait ability? 2. Is the functional improvement (gait speed) achieved with the BCI treatment superior to the standard MI+FES+VR treatment? 3. Is the recoveriX-based therapy as safe as the standard treatment? Participants will have to perform a complete assessment to evaluate their functionality before and after the intervention (motor skills, walking ability, impact of the disease in daily living activities). Patients in the BCI group will receive 25 sessions (3 sessions per week) of BCI training with FES and VR feedback (24 sessions in total). Patients in the control group will receive 25 sessions (3 sessions per week) of FES + VR therapy. Patients in the control group will receive the same instructions as the experimental but will not wear the EEG cap.

Interventions

DEVICErecoveriX

The intervention utilizes the recoveriX PRO system. This is a neurofeedback therapy device that combines Brain-Computer Interface based motor imagery, functional electrical stimulation (FES), and virtual reality (VR). This approach enables participants to engage in motor imagery exercises while receiving real-time feedback based on neural signals. Participants will complete a total of 25 recoveriX sessions, scheduled at 3 sessions per week, with each session lasting 1 hour.

DEVICEControl

The participants will train the Motor Imagination (MI) combined with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback. Feedback provided to the patients will not be linked to the neural signals. The amount of stimulation delivered by the feedback devices (FES and VR) will be similar to the experimental group.

Sponsors

g.tec medical engineering GmbH
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 6-months or more post stroke * With a restriction of the lower extremities preventing the persons from activities of daily life * Participants must be German speaking. * Demonstrate intact cognition to provide informed consent and follow instructions. * Be able to perform TUG and 10MWT (3 times).

Exclusion criteria

* Debilitating conditions or vision impairment that would impede full participation in the study. * Other neurological conditions affecting the motor system or the compliance to the therapy (for example Polyneuropathy or Musculoskeletal Diseases). * Uncontrolled epilepsy or seizures * Significant circulatory disturbances of the stimulated extremities * Inability to independently maintain the seated position (without assistance) for about 60 minutes. * Pregnant * Active or passive implanted medical devices such as pacemakers which do not allow the use of FES. * Implanted metallic fragments in the upper and lower extremities which can limit the use of FES. * Under the influence of anesthesia or similar medication. * With fractures or lesions in the extremity to be stimulated. * Inadequate control of a BCI system. * Sensory disorders which can significantly affect the patient's ability to feel pain and to react to unsuitable proprioceptive stimuli. * Botulinum toxin treatment of his/her paretic lower limb during this study

Design outcomes

Primary

MeasureTime frameDescription
10 Meter Walk TestFrom enrollment to the end of treatment at 8 weeksThe 10MWT assesses walking speed in meters per second over a short distance and is one of the most used to evaluate functional mobility, gait, and balance for lower limb therapy. This is a metric and continuous variable. The 10MWT is used for clinical purposes and in research. It supports the assessment of the degree of damage and describes the recovery of lower extremity after a stroke. Individuals walk 10 meters without assistance and the time is measured for the intermediate 6 meters to allow for acceleration and deceleration. Assistive devices can be used but should be kept consistent and documented from test to test. If physical assistance is required to walk, the 10MWT should not be performed. Patients will receive the following instructions: "Walk as fast as you can safely walk and stop when you reach the far mark."

Secondary

MeasureTime frameDescription
Timed Up and Go testFrom enrollment to the end of treatment at 8 weeksThis test assesses the time that patient needs to get out of chair, walk 3 meters, turn around, walk back 3 meters, and sit down again. The increase in TUG score is consistent with the symptomatology of stroke manifested as muscle weakness and spasticity. Muscle weakness and spasticity are characterized by difficulty in generating appropriately timed and sufficient muscle force to accomplish a given functional task, which could explain the lengthened time score of TUG in subjects with stroke. This is a metric and continuous variable.
Modified Ashworth ScaleFrom enrollment to the end of treatment at 8 weeksThe MAS assesses the spasticity in patients after the CNS damages. This is an ordinal scale with 6 levels. Score criteria: * 0 - No increase in muscle tone. * 1 - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension. * 1+ - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion (ROM). * 2 - More marked increase in muscle tone through most of the ROM but affected part(s) easily moved. * 3 - Considerable increase in muscle tone, passive movement difficult. * 4 - Affected part(s) rigid in flexion or extension. The test should not be performed more than three times for each joint (knee and ankle); If it would be done more than three times, the short-term effect of a stretch could influence the score.

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026